|
|||||
|
|
Delayed minocycline inhibits ischemia-activated matrix metalloproteinases 2 and 9 after experimental stroke |
|
| Authors: | Livia S Machado Anna Kozak Adviye Ergul David C Hess Cesario V Borlongan Susan C Fagan |
| Affiliation: | (1) Program in Clinical and Experimental Therapeutics, Clinical Pharmacy Department, College of Pharmacy, University of Georgia, Augusta, GA, USA;(2) Veteran's Affairs Medical Center, Downtown Division, Augusta, GA, USA;(3) Vascular Biology Center, Medical College of Georgia, Augusta, GA, USA;(4) Department of Neurology, Medical College of Georgia, Augusta, GA, USA |
| Abstract: | BackgroundMatrix metalloproteinases 2 and 9 (MMP-2 and MMP-9) are increased in the brain after experimental ischemic stroke in rats. These two proteases are involved with the degradation of the basal lamina and loss of stability of the blood brain barrier that occurs after ischemia and that is associated with thrombolytic therapy in ischemic stroke. Minocycline is a lipophilic tetracycline and is neuroprotective in several models of brain injury. Minocycline inhibits inflammation, apoptosis and extracellular matrix degradation. In this study we investigated whether delayed minocycline inhibits brain MMPs activated by ischemia in a model of temporary occlusion in Wistar rats. |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |